Chronic inflammatory demyelinating polyneuropathy

Revision as of 18:06, 12 September 2020 by Mtjordan91 (talk | contribs) (→‎Diagnosis)

Background

  • Prevalence of 1 to 2 per 100,000 adults
  • Acute variant is Guillain-Barre syndrome
    • GBS is self limited whereas CIPD is progressive for more than two months

Clinical Features

  • Symmetrical proximal and distal muscle weakness that is progressive for GREATER than two months
  • Impaired sensation
  • Areflexia
  • Elevated CSF protein
  • EMG studies consistent with demyelination
  • Nerve demyelination on nerve biopsies
  • Can be relapsing or chronic and progressive

Differential Diagnosis

Weakness

Evaluation

Workup

' American Academy of Neurology Saperstein Criteria Inflammatory Neuropathy Cause and Treatment Group
Presentation Motor and sensory dysfunction in > 1 limb Major: symetric proximal and distal weakness; Minor: Exclusive distal weakness or sensory loss Progressive or relapsing motor and sensory dysfunction of > 1 limb
Time course in months ≥ 2 months ≥ 2 > 2
Reflexes Reduced or absent Reduced or absent Reduced or absent
EMG criteria Any 3 of the following 4 criteria: partial conduction block of ≥1 motor nerve, reduced conduction velocity of ≥2 motor nerves, prolonged distal latency of ≥2 motor nerves, or prolonged F-wave latencies of ≥2 motor nerves or the absence of F waves 2 of the 4 AAN electrodiagnostic criteria Partial conduction block of ≥2 motor nerves and abnormal conduction velocity or distal latency or F-wave latency in 1 other nerve; or, in the absence of partial conduction block, abnormal conduction velocity, distal latency, or F-wave latency in 3 motor nerves; or electrodiagnostic abnormalities indicating demyelination in 2 nerves and histologic evidence of demyelination
CSF WBC < 10/mm^3, negative VDRL' elevated protein Protein > 45mg/dL; WBC <10/mm^3 Recommended but not mandatory
Biopsy Demylelination and remyelination Demyelination Not mandatory

Management

Disposition

See Also

External Links

References